No mice rejected MC38‐OVAdim s.c. tumors (0/15) after treatment with cIg or anti‐RANKL antibody, while treatment with anti‐PD‐1 antibody alone resulted in few tumor rejections (1/15). Here, TNFSF11 is linked to neoplasm.